Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 3Dermatologic 3Sarcoma 2Lymphoid 2Head & Neck 2Gynecologic 2Genitourinary 2Breast 2Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Large B-Cell, Diffuse 25Multiple Myeloma 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Mantle-Cell 17Lymphoma, Non-Hodgkin 14Lymphoma, T-Cell 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, B-Cell 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Mycosis Fungoides 8Leukemia, Biphenotypic, Acute 8Lymphoma, Large-Cell, Anaplastic 7Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Leukemia, Myelomonocytic, Chronic 5Histiocytosis, Langerhans-Cell 5Glioma 5Wilms Tumor 4Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Rhabdoid Tumor 4Medulloblastoma 4

Interventions

fludarabine 4Cyclophosphamide 4pembrolizumab 3Specimen Handling 3aflibercept 2X-Rays 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Dasatinib 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1epacadostat 1entinostat 1dostarlimab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Biopsy × Lymphoid × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡